Marshall Financial Group LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 84.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,607 shares of the company's stock after selling 29,354 shares during the quarter. Marshall Financial Group LLC's holdings in Novo Nordisk A/S were worth $269,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after buying an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after buying an additional 1,587 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company's stock valued at $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $314,000. Institutional investors own 11.54% of the company's stock.
Novo Nordisk A/S Stock Down 1.4%
Shares of NYSE NVO opened at $46.52 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a market cap of $207.71 billion, a PE ratio of 11.37, a P/E/G ratio of 4.30 and a beta of 0.76. The company's fifty day simple moving average is $47.24 and its 200 day simple moving average is $44.61. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.
Novo Nordisk A/S Cuts Dividend
The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a dividend yield of 254.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 42.79%.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on NVO. Weiss Ratings raised Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. BMO Capital Markets reissued a "market perform" rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Finally, Nordea Equity Research upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $64.94.
Get Our Latest Report on Novo Nordisk A/S
Trending Headlines about Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
- Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
- Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
- Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
- Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market
Novo Nordisk A/S Company Profile
(
Free Report)
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
